The hazard ratio for the OS was 0.82 (95% CI, 0.63–1.07) with a log-rank p -value of 0.048, suggesting a trend toward improved survival with atezolizumab, although this result approaches statistical significance in this interim analysis, with data maturity at 43%.
← all excerpts
The Role of Immunotherapy in MMR-Deficient Endometrial Carcinoma: State of the Art and Future Perspectives.
1
—
—